{"id":"flonoltinib-maleate","safety":{"commonSideEffects":[{"rate":"null","effect":"Myelosuppression"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1200659","moleculeType":"Small molecule","molecularWeight":"492.53"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by selectively inhibiting the BCR-ABL1 protein, which is responsible for the proliferation of cancer cells in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). This inhibition leads to the suppression of cancer cell growth and proliferation.","oneSentence":"Flonoltinib maleate is a tyrosine kinase inhibitor that targets the BCR-ABL1 protein.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:54:35.191Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic myeloid leukemia (CML)"},{"name":"Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)"}]},"trialDetails":[{"nctId":"NCT07232290","phase":"PHASE2","title":"Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera","status":"RECRUITING","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","startDate":"2025-09-23","conditions":"Polycythemia Vera (PV)","enrollment":60},{"nctId":"NCT07317700","phase":"PHASE3","title":"A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis","status":"RECRUITING","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","startDate":"2026-02-13","conditions":"MF","enrollment":105},{"nctId":"NCT07443306","phase":"PHASE2","title":"A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Medium to High Risk Myelofibrosis","status":"NOT_YET_RECRUITING","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","startDate":"2026-04-30","conditions":"MF","enrollment":64},{"nctId":"NCT05153343","phase":"PHASE1, PHASE2","title":"Safety of Flonoltinib Maleate Tablets for the Treatment of Patients With Myeloproliferative","status":"COMPLETED","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","startDate":"2021-12-27","conditions":"Myeloproliferative Neoplasm (MPN), Myelofibrosis，MF","enrollment":31},{"nctId":"NCT07193576","phase":"PHASE1","title":"A Pharmacokinetic Study of the Food Effect on Flonoltinib Maleate Tablets","status":"COMPLETED","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","startDate":"2024-08-04","conditions":"Heathly Subjects","enrollment":24},{"nctId":"NCT06387966","phase":"PHASE1","title":"A Phase I Clinical Study of Flonoltinib Maleate Tablets in Healthy Subjects","status":"COMPLETED","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","startDate":"2024-03-18","conditions":"Heathly Subjects","enrollment":40},{"nctId":"NCT06457425","phase":"PHASE2","title":"A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis","status":"RECRUITING","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","startDate":"2024-05-06","conditions":"MF,PMF,PPV-MF,PET-MF","enrollment":75},{"nctId":"NCT05713279","phase":"NA","title":"Study of Flonoltinib Maleate Tablets in the Treatment of Severe Novel Coronavirus (COVID-19) Infection","status":"UNKNOWN","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","startDate":"2023-01-19","conditions":"COVID-19","enrollment":66},{"nctId":"NCT05115344","phase":"PHASE1","title":"Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors","status":"UNKNOWN","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","startDate":"2021-11-12","conditions":"Myeloproliferative Neoplasm (MPN), Myelofibrosis，MF","enrollment":31}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Flonoltinib Maleate","genericName":"Flonoltinib Maleate","companyName":"Chengdu Zenitar Biomedical Technology Co., Ltd","companyId":"chengdu-zenitar-biomedical-technology-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Flonoltinib maleate is a tyrosine kinase inhibitor that targets the BCR-ABL1 protein. Used for Chronic myeloid leukemia (CML), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}